



# Basic Annual Drug List Updates

April 2019

TRADE NAME (generic name) or generic name	Brand/Generic	Description of Change
AIMOVIG (ereenumab-aooe subcutaneous soln auto-injector 70 mg/ml)	Brand	Addition, Preferred Status
CELLCEPT (mycophenolate mofetil cap 250 mg)	Brand	Addition, Preferred Status, generics available
CELLCEPT (mycophenolate mofetil tab 500 mg)	Brand	Addition, Preferred Status, generics available
DELSTRIGO (doravirine-lamivudine-tenofovir df tab 100-300-300 mg)	Brand	Addition, Preferred Status
DIVIGEL (estradiol td gel 0.75 mg/0.75gm (0.1%))	Brand	Addition, Preferred Status
EMGALITY (galcanezumab-gnlm subcutaneous soln auto-injector 120 mg/ml)	Brand	Addition, Preferred Status
EMGALITY (galcanezumab-gnlm subcutaneous soln prefilled syr 120 mg/ml)	Brand	Addition, Preferred Status
EPIDIOLEX (cannabidiol soln 100 mg/ml)	Brand	Addition, Preferred Status
GRANIX (tbo-filgrastim subcutaneous inj 300 mcg/ml)	Brand	Addition, Preferred Status
GRANIX (tbo-filgrastim subcutaneous inj 480 mcg/1.6ml (300 mcg/ml))	Brand	Addition, Preferred Status
MITIGARE (colchicine cap 0.6 mg)	Brand	Addition, Preferred Status
NIVESTYM (filgrastim-aafi soln prefilled syringe 300 mcg/0.5ml)	Brand	Addition, Preferred Status
NIVESTYM (filgrastim-aafi soln prefilled syringe 480 mcg/0.8ml)	Brand	Addition, Preferred Status
NOVOLIN 70/30 FLEXPEN (insulin nph & regular susp pen-inj 100 unit/ml (70-30))	Brand	Addition, Preferred Status
ORLISSA (elagolix sodium tab 150 mg (base equiv))	Brand	Addition, Preferred Status
ORLISSA (elagolix sodium tab 200 mg (base equiv))	Brand	Addition, Preferred Status
PROGRAF (tacrolimus cap 0.5 mg)	Brand	Addition, Preferred Status, generics available
PROGRAF (tacrolimus cap 1 mg)	Brand	Addition, Preferred Status, generics available
PROGRAF (tacrolimus cap 5 mg)	Brand	Addition, Preferred Status, generics available
SYMDEKO (tezacaftor-ivacaftor 100-150 mg & ivacaftor 150 mg tab tbpk)	Brand	Addition, Preferred Status
XARELTO (rivaroxaban tab 2.5 mg)	Brand	Addition, Preferred Status
ZORTRESS (everolimus tab 1 mg)	Brand	Addition, Preferred Status

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent Licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Illinois (BCBSIL) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.